By Fineline Cube Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) has entered into a strategic exclusive licensing agreement with global biopharmaceutical leader AbbVie Inc. (NYSE: ABBV) for its Nav1.8 pain program. The deal grants AbbVie worldwide rights (excluding Mainland China, Hong Kong, and Macau) to develop, manufacture, and commercialize two selective Nav1.8 inhibitors, HSK55718 (IV) and HSK51155 (oral), for pain-related indications.
Deal Financials & Structure
| Component | Detail |
|---|---|
| Upfront Payment | $30 million to Haisco |
| Potential Milestones | Up to $715 million |
| Royalties | Tiered, based on future net sales |
| R&D Support | AbbVie to fund costs up to clinical proof-of-concept |
| Territory | Worldwide ex-China (Mainland, HK, Macau) |
| Assets | HSK55718 (Phase I IV) & HSK51155 (Preclinical oral) |
Drug Profile & Mechanism
- Target: Nav1.8, a voltage-gated sodium channel subtype predominantly expressed in peripheral pain-sensing neurons.
- Mechanism of Action: Selective inhibition of Nav1.8 blocks the abnormal firing of these neurons, thereby reducing the transmission of pain signals to the central nervous system, offering a potentially non-opioid approach to pain management.
- Pipeline Status:
- HSK55718: Intravenous formulation currently in Phase I trials in China.
- HSK51155: Oral formulation in preclinical development.
Strategic Rationale
- De-risking & Global Reach: For Haisco, the partnership provides substantial non-dilutive capital and leverages AbbVie’s world-class expertise in pain drug development and global commercialization, significantly de-risking the program while allowing Haisco to retain full control in its home market.
- Portfolio Expansion: For AbbVie, this acquisition adds a novel, non-opioid mechanism to its robust pain pipeline, addressing a critical area of unmet need and diversifying its therapeutic offerings beyond immunology and neuroscience.
- Flexible Development: AbbVie’s commitment to fund R&D through proof-of-concept ensures rigorous validation of the assets before major milestone commitments, aligning incentives for both parties.
Market Context
- Pain Therapeutics Landscape: The search for effective, non-addictive pain therapies remains a top priority for the pharmaceutical industry. Nav1.8 inhibitors represent a promising, genetically validated target class.
- Chinese Innovation: This high-value deal underscores the growing maturity of Chinese biopharma, where companies like Haisco are developing globally competitive, novel assets that attract partnerships with top-tier Western firms.
- Financial Catalyst: The $30 million upfront provides immediate balance sheet strength for Haisco, while the potential $745 million total deal value represents a major upside for shareholders.
Forward-Looking Statements
This brief outlines a strategic collaboration. The achievement of milestones and payment of royalties is contingent upon the successful development and commercialization of the licensed products, which is subject to significant scientific, regulatory, and market risks. There can be no assurance of success.-Fineline Info & Tech